On 4 November 2023 the decree of the Ministry of Industry and Trade No. 2701 dated 21 July 2023, which approved a new list of goods for parallel import and recognized the decree of the Ministry of Industry and Trade No. 1532 dated 19 April 2022 and all the amending decrees as null and void, comes into force.
By its Ruling of 25.09.2023 in case No. A40-185112/2022, the Ninth Commercial Court of Appeal ordered the pharmaceutical company Vertex, the right holder of a series of patents for the drug Trikafta (INN: Ivacaftor+Tezacaftor+Elexacaftor, Ivacaftor), to grant a simple (non-exclusive) license to the Russian pharmaceutical company MIK under Article 1362(1) of the Russian Civil Code (insufficient use of patents).
Lidings’ IP team has successfully secured recognition of the Doppelherz brand as a well-known trademark specifically for dietary supplements, setting a valuable precedent. The interests of the client, the German pharmaceutical company Queisser Pharma, which owns the brand, were represented by Boris Malakhov, Partner, and Vladislav Ryabov, Senior Associate.
The President has signed a law which may have an impact on Internet users and website owners.
The Law amends the Act "On Information, Information Technologies and the Protection of Information" and the Act "On Communications". The law introduces new requirements for the owners of Internet sites and their users.
Lidings Intellectual Property team has helped a major Russian manufacturer of pharmaceuticals, Pharmnovations, to achieve the annulment of the marketing authorization for a generic drug of a competitor company.
On 29 June 2023, Federal law of 28 June 2022 No. 193-FZ came into force, amending Part 4 of the Russian Civil Code, including the subjects that can be trademark holders.
April 26th,2023 annual conference Pharmaceuticals – 2023: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.
As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss topical issues of industry regulation, changes in the pharmaceutical market in the ongoing era of sanctions and talk about how to protect intellectual property.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.